These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22990266)

  • 21. Companies throw their weight behind new antiobesity drugs.
    Cahoon L
    Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442
    [No Abstract]   [Full Text] [Related]  

  • 22. Update on pharmacology of obesity: benefits and risks.
    Cabrerizo García L; Ramos-Leví A; Moreno Lopera C; Rubio Herrera MA
    Nutr Hosp; 2013 Sep; 28 Suppl 5():121-7. PubMed ID: 24010752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over-the-counter orlistat. A weight loss "Alli" or adversary on the horizon.
    Anderson T
    AWHONN Lifelines; 2006; 10(5):418-21. PubMed ID: 17069574
    [No Abstract]   [Full Text] [Related]  

  • 24. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM
    Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Obesity Pharmacotherapy: The Intercontinental Regulatory Divide.
    Krentz AJ; Fujioka K; Hompesch M
    Drugs; 2015 Jun; 75(9):931-3. PubMed ID: 25963328
    [No Abstract]   [Full Text] [Related]  

  • 26. Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.
    Wynn RL
    Gen Dent; 2013; 61(1):11-3. PubMed ID: 23302354
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacological therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fat of the matter.
    Nat Med; 2012 Aug; 18(8):1155. PubMed ID: 22869166
    [No Abstract]   [Full Text] [Related]  

  • 29. Market watch: upcoming market catalysts in Q3 2010.
    Hay M
    Nat Rev Drug Discov; 2010 Jul; 9(7):507. PubMed ID: 20592737
    [No Abstract]   [Full Text] [Related]  

  • 30. New obesity pill: new hopes, old fears.
    Lancet; 2010 Dec; 376(9758):2042. PubMed ID: 21168038
    [No Abstract]   [Full Text] [Related]  

  • 31. Panel advises against rimonabant approval.
    Traynor K
    Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490
    [No Abstract]   [Full Text] [Related]  

  • 32. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find?
    Downey M; Still C; Sharma AM
    Curr Opin Endocrinol Diabetes Obes; 2011 Oct; 18(5):321-7. PubMed ID: 21878755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Employers, others not sold on new anti-obesity drugs.
    Reinke T
    Manag Care; 2012 Sep; 21(9):33-6. PubMed ID: 23050423
    [No Abstract]   [Full Text] [Related]  

  • 34. Food and Drug Administration's Obesity Drug Guidance Document: a short history.
    Colman E
    Circulation; 2012 May; 125(17):2156-64. PubMed ID: 22547756
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA
    Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug treatment of obesity.
    Bray GA; Ryan DH
    Psychiatr Clin North Am; 2011 Dec; 34(4):871-80. PubMed ID: 22098810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
    Bays HE; Gadde KM
    Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orlistat: current status in clinical therapeutics.
    McClendon KS; Riche DM; Uwaifo GI
    Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA-Approved Anti-Obesity Drugs in the United States.
    Daneschvar HL; Aronson MD; Smetana GW
    Am J Med; 2016 Aug; 129(8):879.e1-6. PubMed ID: 26949003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updates on obesity pharmacotherapy.
    Velazquez A; Apovian CM
    Ann N Y Acad Sci; 2018 Jan; 1411(1):106-119. PubMed ID: 29377198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.